Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

roche products ltd - levodopa; benserazide hydrochloride - oral capsule - 100mg ; 25mg

Īrija - angļu - HPRA (Health Products Regulatory Authority)

roche products limited - levodopa, benserazide hydrochloride - capsules hard - 200/50 milligram - dopa and dopa derivatives

Malta - angļu - Medicines Authority

roche products limited 6 falcon way, shire park, welwyn garden city, al7 1tw, united kingdom - benserazide, levodopa - hard capsule - benserazide 50 mg levodopa 50 mg - anti-parkinson drugs

Malta - angļu - Medicines Authority

roche products limited 6 falcon way, shire park, welwyn garden city, al7 1tw, united kingdom - benserazide, levodopa - hard capsule - benserazide 25 mg levodopa 100 mg - anti-parkinson drugs

Malta - angļu - Medicines Authority

roche products limited 6 falcon way, shire park, welwyn garden city, al7 1tw, united kingdom - benserazide, levodopa - hard capsule - benserazide 50 mg levodopa 200 mg - anti-parkinson drugs

Malta - angļu - Medicines Authority

roche products limited 6 falcon way, shire park, welwyn garden city, al7 1tw, united kingdom - benserazide, levodopa - prolonged-release capsule - benserazide 25 mg levodopa 100 mg - anti-parkinson drugs

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 57 mg (equivalent: benserazide, qty 50 mg); levodopa, quantity: 200 mg - tablet, uncoated - excipient ingredients: iron oxide red; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate; mannitol; pregelatinised maize starch; docusate sodium; ethylcellulose - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg); levodopa, quantity: 100 mg - capsule, hard - excipient ingredients: mannitol; indigo carmine; iron oxide yellow; hypromellose; titanium dioxide; magnesium stearate; purified talc; gelatin; hydrogenated vegetable oil; povidone; calcium hydrogen phosphate dihydrate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; iron oxide red; ethanol absolute; potassium hydroxide; ammonia - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism. madopar hbs is indicated for patients presenting with all types of fluctuations in response (i.e. "peak dose dyskinesia" and "end of dose deterioration") and for better control of nocturnal symptoms.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 14.25 mg (equivalent: benserazide, qty 12.5 mg); levodopa, quantity: 50 mg - tablet, dispersible - excipient ingredients: magnesium stearate; pregelatinised maize starch; citric acid; microcrystalline cellulose - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

Beļģija - angļu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

roche sa-nv - levodopa 200 mg; benserazide hydrochloride 57 mg - eq. benserazide 50 mg - tablet - 200 mg - 50 mg - levodopa 200 mg; benserazide hydrochloride 57 mg - levodopa and decarboxylase inhibitor